Skip to main content
OpenTrials
Completed

NCT Number: NCT04630574

Characterization and Quantification of Motor Speech Disorders in Huntington's Disease: Identification of Acoustic Markers

The study proposes to identify deviant speech dimensions in patients with HD at presymptomatic and declared stages of the disease, compared to healthy subjects, using the computerized MonPaGe speech protocol. This tool is based on a multidimensional and quantified assessment of voice and speech, by a set of targeted acoustic and perceptual criteria.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Huntington's disease (HD) is a neurodegenerative disorder of the central nervous system, of genetic etiology. It manifests itself in motor, cognitive and psychiatric disorders, which progressively worsen until the patient is grabbed. Motor speech performance disorders are present from the early stage of the disease. These difficulties, which progressively worsen until the end of the patient's life, lead to a communication disorder and constitute a major handicap with social withdrawal, loss of self-esteem and isolation, which are always very painfully experienced by patients and their entourage. Dysarthria in the HD has been very little studied, which makes its speech therapy uncodified. According to the most widely used classification by speech therapists and neurologists, the Darley classification (1975), the speech disorders observed in the HD are included in the heterogeneous group of hyperkinetic dysarthria, whose contours and properties are ill-defined. In this context, a more precise knowledge of speech disorders in the HD appears necessary to identify and characterize the different types of dysarthria and the dysfunctions associated with each level of production (respiration, phonation, resonance, articulation, prosody) and thus improve speech language therapy.

The investigators propose to use an acoustic evaluation to support the perceptual evaluation, available in the MonPaGe protocol, to describe the fine characteristics of the speech disorders in the HD and to define objective markers of dysarthria in this disease for francophone patients.

Each patient is seen in the framework of his annual follow-up consultation in the Competence Center mdH of Bordeaux University Hospital or in the Reference Center mdH of the hospital Henri Mondor of Créteil, for an evaluation of his speech with the computerized tool MonPaGe. A first speech evaluation with the BECD (Auzou, 2006) during 30 minutes is proposed to exclude very severe dysarthria. At the end of this rapid test subtest, the subjects who obtain a perceptive score <16 are offered the complete assesment of the MonPaGe computerized protocol (30 minutes).The application records directly and anonymously stores speech productions made by the patient.The productions are transmitted to the Phonetics and Phonology Laboratory of Paris (UMR 7018 CNRS / Sorbonne Nouvelle), via a secure large data exchange server and are subject to a perceptual and acoustic evaluation a posteriori.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • major patients
  • francophone patients
  • Huntington's disease carriers confirmed by molecular biological analysis
  • carriers of pre-symptomatic Huntington's disease: Total Motor Score of the Unified Huntington's Disease Rating Scale <5
  • carriers of Huntington's disease at a declared stage: Total Motor Score of the Unified Huntington's Disease Rating Scale ≥ 5
  • followed in the Competence Center Huntington's disease Bordeaux Hospital or in the Reference Center Huntington's disease Henri Mondor Hospital of Créteil
  • affiliates or beneficiaries of a social security scheme
  • Finally, a free, informed and express consent of the patient must be collected.

Exclusion criteria

  • Huntington's disease patients with severe dysarthria (BECD score> 16), acoustic analysis not being possible on unintelligible speech
  • patients placed under the protection of justice

Treatment and study plan

Speech evaluation with the clinical evaluation of dysarthria

Other

A first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.

complete assessment of the MonPaGe computerized protocol

Other

The application records directly and anonymously stores speech productions made by the patient.

Primary outcomes

  1. Determination of the intelligibility score.

    Time frame: Day 1

    Defined as the number of words correctly recognized by the evaluator (score out of 15).

  2. Determination of the maximum phonation time.

    Time frame: Day 1

    Expressed in milliseconds.

  3. Determination of the phonation characteristics.

    Time frame: Day 1

    Described as the mean and standard deviation of fundamental frequency (in Hz),

  4. Determination of the intensity modulation capacities.

    Time frame: Day 1

    Based on a scale of 0 to 4.

  5. Determination of the Coarticulation.

    Time frame: Day 1

    Expressed in Hz. Extracted from the spectral properties of the acoustic signal of certain words.

  6. Determination of the prosody.

    Time frame: Day 1

    assessed on a scale 0 to 4 on particular sentences.

  7. Determination of the diadocokinesies,

    Time frame: Day 1

    assessed on two scales: precision (0 to 4) and control (0 to 4).

  8. Determination of the articulation rate.

    Time frame: Day 1

    expressed in syllabs per second.

Secondary outcomes

  1. Determination of the Huntington's disease stage.

    Time frame: Day 1

    The Huntington's disease stage will be determined based on the Total Functional Capacity (TFC) and the Total Motor Score (TMS) scales of the Unified Huntington's Disease Rating Scale:

    • pre-symptomatic stage: TFC = 13 / TMS <5
    • light stage: TFC ≥11 / TMS 5 to 20
    • moderate stage: TFC = 7 to 10 / TMS: 20 to 40
  2. Determination of the clinical motor forms of the Huntington's disease.

    Time frame: Day 1

    The clinical motor forms of Huntington disease will be determined by the motor UHDRS scale (Total Motor Score), which evaluates oculomotricity, skill and manual planning, bradykinesia, dystonia and rigidity, chorea and walking, balance, lingual protrusion and dysarthria.

  3. Determination of the level of cognitive impairment

    Time frame: Day 1

    The level of cognitive impairment will be assessed by the cognitive score as per the Unified Huntington's Disease Rating Scale.

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Collaborators

  • Centre National de la Recherche Scientifique, France

Registry information

Acronym: TPMH

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Nov 16, 2020
Registry last updated
Feb 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.